Decade af­ter $8B deal, Roche of­floads In­ter­Mune to mys­te­ri­ous spe­cial­ty phar­ma

Roche’s $8 bil­lion In­ter­Mune ac­qui­si­tion, dis­closed a decade ago, is now be­ing hand­ed to a spe­cial­ty phar­ma­ceu­ti­cal com­pa­ny.

Cay­man Is­lands-based Lega­cy Phar­ma is run by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER